News
HKMPF
19.07
NaN%
--
Hikma Pharmaceuticals Balances Strong H1 With Cautious Outlook
TipRanks · 3d ago
Hikma strengthens board with appointment of former Haleon CFO Tobias Hestler
TipRanks · 4d ago
Hikma lifts profit and R&D spend as it reaffirms 2026 outlook
TipRanks · 4d ago
Hikma updates market on share capital and voting rights
TipRanks · 6d ago
Hikma advances $250m buyback, cuts share count and voting base
TipRanks · 6d ago
Weekly Report: what happened at HKMPF last week (0727-0731)?
Weekly Report · 6d ago
Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run
Seeking Alpha · 07/31 21:15
Hikma advances $250m share buyback, cancels repurchased stock
TipRanks · 07/27 10:52
Weekly Report: what happened at HKMPF last week (0720-0724)?
Weekly Report · 07/27 09:12
Weekly Report: what happened at HKMPF last week (0713-0717)?
Weekly Report · 07/20 09:11
Hikma Advances $250 Million Share Buyback, Cuts Share Count
TipRanks · 07/20 08:27
Hikma Pharmaceuticals initiated with a Buy at Citi
TipRanks · 07/16 08:20
Hikma Pharmaceuticals (HIK) Initiated with a Buy at Citi
TipRanks · 07/16 06:15
Hikma Cancels More Shares as $250m Buyback Passes 10 Million Mark
TipRanks · 07/13 09:42
Weekly Report: what happened at HKMPF last week (0706-0710)?
Weekly Report · 07/13 09:12
Weekly Report: what happened at HKMPF last week (0629-0703)?
Weekly Report · 07/06 09:12
Hikma Advances $250m Share Buyback, Tightens Free-Float
TipRanks · 07/06 08:42
Weekly Report: what happened at HKMPF last week (0622-0626)?
Weekly Report · 06/29 09:12
Hikma Advances $250m Buyback, Cuts Share Count and Voting Free Float
TipRanks · 06/29 08:52
Hikma Pharmaceuticals (HIK) Receives a Buy from Deutsche Bank
TipRanks · 06/24 17:05
More
Webull provides a variety of real-time HKMPF stock news. You can receive the latest news about Hikma Pharma through multiple platforms. This information may help you make smarter investment decisions.
About HKMPF
Hikma Pharmaceuticals PLC is a multinational pharmaceutical company engaged in the development, manufacturing and marketing of a broad range of generic, branded and specialty pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Hikma Rx. It supplies hospitals across North America, Europe and the Middle East and North Africa (MENA) region with generic injectable and specialty medicines, supported by its growing global manufacturing network. It supplies branded generic and in-licensed products from its local manufacturing facilities to retail and hospital customers across the MENA region. Through Hikma Rx, it supplies oral, respiratory and other generic and specialty products to the North American market. Its manufacturing facilities in the United States (US) supply products across a broad range of therapeutic areas, including respiratory, oncology and pain management, serving customers in both the US and Canada.